Study in Primary Mitochondrial Myopathy (PMM) Awarded

GCT has been selected to run a new project in patients diagnosed with PMM by its long-term Client. This Phase 2, multicenter, double-blind, placebo-controlled study will be managed by GCT team in Czech Republic and Hungary. 

Primary Mitochondrial Myopathies are a group of genetic disorders affecting the skeletal muscle. The main symptoms of PMM are muscle fatigue, weakness, and exercise intolerance. The severity of these symptoms varies greatly from one person to another, and always affects the quality of life. It is caused by a mutation in genes of the mitochondria, and is one of the most common metabolic diseases. The new treatment aims to prove its safety and efficacy against the main symptoms of PMM.

GCT is responsible for a wide scope of services ranging from feasibility analysis and regulatory support to monitoring, site contracting and management. The trial is currently in startup in both countries with the sites already selected.

GCT Ukraine is Moving to a Larger Facility

Global Clinical Trials first established its operations and a physical office in Ukraine in 2006. Ever since then, the country has been a highly fruitful addition to the company map. It has facilitated and accelerated enrollment of patients significantly for both local and global clinical trials.

Projects in various indications, including oncology, ophthalmology, CNS and others were successfully carried out during the years of operation in the country. Despite the global pandemic, Ukraine remained the country with much activity in clinical research in year 2020. We launched 2 new gynecology studies in Endometriosis and a Phase II study in idiopathic pulmonary fibrosis (IPF), a rare pulmonary indication. GCT team was also awarded a trial in COVID-19 infected patients to contribute to the global search for treatment options.

Among other projects, we are presently in the active start-up phase and opening 25 sites for a large global study in non-small lung cancer patients.

It is our pleasure to announce that we are moving to a new location to create an appropriate environment for our growing operations and headcount in the country.

Please update your records with our new address:

UCT Global, LLC

36а Verkhovynna vul.,

03115, Kyiv, Ukraine

The Holiday Season across the globe. It’s time to take the stock of our achievements!

We have endured unprecedented changes in the way we live, interact with each other, and work. This year more than ever, we are committed to remaining a reliable partner by advancing GCT processes both through traditional approaches and with the introduction of more virtual and remote solutions. As the winter holidays are celebrated all over the world and the New Year is just around the corner, our global team wants to take a moment to say thank you for your support and partnership. It motivates us to carry out our mission. Since the beginning, it has always been our priority making lives healthier. We wish you a warm and happy 2021. We look forward to continuing our collaboration in the upcoming year. Wishing you Happy Holidays!

From all of us at Global Clinical Trials

2020 CORPORATE

In 2020 we enhanced the global presence with:

GCT office in Kazakhstan, Almaty
GCT office in Georgia, Tbilisi
GCT office in the Baltic Countries: Estonia, Latvia, and Lithuania

2020 PROJECTS

In 2020 Global Clinical Trials was awarded new projects in the USA, the EU, India, Asia, Russia, and Ukraine. Our Clients entrusted GCT studies in various therapeutic areas: CNS, Oncology, Ophthalmology, Gastroenterology, Infectious Diseases, Rare Diseases, Pulmonary, Women’s Health.

The first local project in the country of Georgia was initiated by GCT in 2020. The observational Phase IV clinical trial in Multiple Sclerosis is a multinational study that was awarded by the US international Big Pharma.

Within the GCT Client base, there are big and medium-size Pharma, Biotech, and Device companies from the USA, Europe, Asia, the Middle East, and Russia.

In spite of the pandemic, GCT was able to achieve the enrollment goals for all studies this year. Remote monitoring and Investigator’s Meetings were in demand this year and played an important role in assuring the safety of patients, GCT employees, and site staff, as well as data integrity.

We provided the diverse scope of clinical trials services, including project management, site selection and management, full regulatory support in different regions, clinical monitoring, EU Legal representation and GDPR support, Medical Monitoring and Pharmacovigilance, logistics of the IMP, and clinical supplies, vendor management and other. In addition, GCT has implemented a number of patient recruitment tools, as well as provided the solution of local booster visits for Sponsors and CROs that do not have local resources and were restricted with travel.


With the emergence of new projects, we were also delivering on our ongoing projects. It is a pleasure to share with you some milestones that have been achieved during 2020:


2020 CONFERENCES & EVENTS

Despite all the complexity of 2020, we utilized the opportunities that this year gave us.

GCT managed to attend several face-to-face events before they all got switched to virtual platforms, including SCOPE Summit in Orlando, the 16th Annual Scientific Meeting organized by ISCTM, Global Alzheimer’s Platform Foundation event, the 13th Clinical Trials on Alzheimer’s Disease Congress (CTAD).

Our global team shifted to virtual platforms and attended many events and conferences dedicated to innovation in the pharmaceutical industry, CNS area advances, updates in drug development, etc.

In May 2020 GCT participated in the COVID-19 Virtual Partnering Event.

Oleg Kurilov, General Director of GCT in Kazakhstan, attended the Virtual Pharmaceutical Marathon.

Represented by Nataliya Katsnelson, Senior Director of Business Development, and Elizaveta Medvedeva, BD Associate, GCT exhibited at the DIA 2020 global annual meeting.

Aleksandr Stiblo, GCT Director of Business Development participated in meetings, panel discussions, round tables, and keynote presentations at the World Vaccine Congress Europe 2020 and Eurasia Pharmaceutical Forum dedicated to the Clinical Research in the region.

Most recently, Dr. Dmytro Mozhynskyy, General Director of GCT in Ukraine participated in the sixth international scientific conference “Clinical Trials of Drugs in Ukraine”, which was a partially virtual and partially face-to-face meeting in Kyiv, Ukraine


Stay tuned and see what 2021 updates we will share. Global Clinical Trials invites you to follow us on social media:

We look forward to more exciting projects
and fruitful partnerships in 2021.
Happy Holidays!

New Scientific Project in Russia

GCT has been awarded a new multinational scientific project in patients diagnosed with Schizophrenia and other related psychiatric disorders.

There is little knowledge of gene-environment, gene-gene and other relevant causal interactions in the development of schizophrenia. The project aims to identify some of the risk factors predisposing patients, as it is vital for effective prevention and finding a potential cure of schizophrenia.

GCT will manage the whole scope of services for the project including the local biosamples logistics and regulatory support.

Why CNS Clinical Trials are More Successful in Eastern Europe

With more than 19 years of experience in conducting CNS trials, we are now seeing that studies in Eastern Europe are becoming more and more popular among sponsors worldwide.

Aside from cost-effectiveness and high incidence rates in CNS disorders, there is another important factor that makes clinical research in EE even more attractive. It is lower placebo response rates in patients.

Placebo response in CNS trials is substantial and increasing. High placebo response rates have become an important problem, especially in the trials taking place in the USA.

Last year, Intra-Cellular ran two identical studies in Bipolar Depression. The 401 trial was entirely conducted in the U.S. and did not meet the primary endpoints due to the high rate of placebo response. Intra-Cellular announced the positive top-line results with significantly lower placebo response rate for the 404 trial, which was conducted globally with most patients recruited in Eastern Europe.

Another global study in Schizophrenia was conducted by ACADIA Pharmaceuticals and showed consistent improvement in psychotic syndromes. Even though it failed to meet the primary endpoints, the analysis by region showed consistent positive results for the European population including patients from Bulgaria, Czechia, Hungary, Poland, Serbia, Ukraine and Russian Federation.

Patients’ high placebo response calls the value of many CNS medications into question. Ever since the issue emerged, the sponsors have been in search for methods to mitigate it.

Many of them have found it useful to diversify the trial by adding regions with potentially lower placebo response rates among patients. One of such regions is Eastern Europe, where GCT established full-service operations and have been running clinical trials since 2001.

GCT is your partner in clinical trials in Eastern Europe because it combines global reach with local expertise. Both GCT CEO, Dr. Eugene Selivra and GCT President, Dr. Jeffrey Apter are trained psychiatrists with 50+ years of combined experience in clinical research. Dr. Jeffrey Apter is a Key Opinion Leader (KOL) in Depression and Alzheimer’s Disease. Moreover, GCT has close ties with the international CNS community and is an expert in the latest innovations in CNS clinical research. 

“AbbVie partnered with Global Clinical Trials in the conduct of Alzheimer’s disease clinical trials in sites across Eastern Europe.  This partnership proved to be invaluable.  Trial results have been published; demonstrating statistical separation of positive control (donepezil) from placebo, low placebo response, and low statistical variability on endpoints, including the primary endpoint,” – George Haig, Pharm.D., former Group Project Leader at AbbVie.

Are you planning a clinical trial in the CNS therapeutic area? Contact our BD team at bd@gctrials.com with any questions or for a free feasibility analysis for your planned clinical program.

GCT to Perform Booster Visits in Russia

The Sponsor is running an international phase III trial in Crohn’s disease. Study recruitment is challenged by initial low incidence of the disease, combined with a big number of competing trials, as well as COVID-19 impact. As an escalation strategy and to reengage sites that are behind on the enrollment, the Sponsor decided to perform booster visits, including on-site visits by GCT team in Russia.

Patient recruitment and retention strategy is a huge part of proactive contingency planning of any the trial. Booster visit is an important component of the planning that allows sites and Sponsors/CROs to get together and develop an action plan to reach the enrollment projections.

We are struggling with patient recruitment in this trial, and under normal circumstances we as a Sponsor make individual visits to each of our sites to boost patient recruitment. Still, the horrid COVID-19 pandemic is keeping us from making individual visits by ourselves, thus forcing us to find alternatives – booster visits made by local CRO. It is the fact that local CROs are more likely to have pre-existing strong relationships with PIs or other personnel who can positively affect patient recruitment. Our aim is to make booster visits to those sites by GCT (with pre-existing relationships and rapport) and to have positive effect in patient recruitment that we are having a hard time with.”

GCT is a full-service clinical research organization operating in Russia since 2001. The company have established strong relationships with PIs and sites countrywide. GCT has scheduled face-to-face meetings with Investigator site teams in Kazan, Irkutsk, St. Petersburg, Moscow, Tomsk and Samara. Moreover, the first visit has already been conducted.

“Nowadays, it has become complicated for Sponsor to closely oversee the process of clinical trials due to travel restrictions. Having a reliable and experienced partner who is able to provide a high-level service and engage the study team is the key to solving this problem” – said Dr. Eugene Selivra, GCT CEO.

Relapsed or Refractory Lymphoma Trial in Russia

Princeton, NJ, USA, Nov 12, 2020

Global Clinical Trials is initiating a Phase I clinical study in Relapsed or Refractory Lymphoma for a US biotechnology company, OncoTartis, Inc.

“I am excited that clinical trials with our promising drug candidate OT-82 will now include several clinical sites in Russia. In preparation for this trial, our team was impressed by the knowledge, experience, and professionalism of people at GCT. I am confident that everything possible will be done to bring our trial to success despite the tough challenges posed by the Covid-19 pandemic” – Alexander Polinsky, Ph.D., Founder & CEO, OncoTartis.

GCT will be responsible for the local study management throughout all stages of the trial, including start-up activities, regulatory submission to Ministry of Health and Local Ethics Committees, project and site management, clinical monitoring, and the full cycle of the complex study logistics. GCT team will organize the IMP and CTMs import, customs clearance and local distribution to the sites, as well as biosamples export to the central laboratory. The IMP, ancillary supplies, equipment, and biosamples will be stored at GCT depot in Saint-Petersburg under required temperature regimes. In addition, GCT will manage the IMP preparation that must be performed individually before each administration. Our team is looking forward to achieving the first milestone – receiving the regulatory approval.

We would like to thank OncoTartis for entrusting GCT such an important project. Given the limited number of treatment options available for this indication, we are excited to make our own humble contribution to the development of one,“ said Dr. Eugene Selivra, GCT CEO.

Proving clinical research services to pharmaceutical, biotech and device companies for over 19 years, GCT has gained extensive experience in various oncology studies, including multinational projects for European, US and Asian Sponsors.

Endometriosis safety follow-up study in Ukraine

Princeton, NJ, USA, Nov 12, 2020

Global Clinical Trials launches new gynecology study in Ukraine. The project is sponsored by young EU biopharma company focused on research in women’s health.

It is a multicenter, open-label, single-arm Phase III study in 160 patients suffering from endometriosis. The study is designed to assess the safety and efficacy of the Investigational Product and will be conducted at up to 13 sites in Ukraine.

GCT team is providing the local support for the study including regulatory affairs, study and site management, clinical monitoring and logistics of IMP and clinical supplies.

“GCT team appreciates the trust of our partners and the repeat business they bring to us. At this time Ukraine is prepared for new studies more than ever with joint efforts of the regulatory authorities, healthcare professionals, and experts in the field,” – said Dr. Eugene Selivra, GCT CEO.

GCT enhances European presence through a strategic acquisition in Baltic States

Princeton, NJ, USA, Nov 11, 2020

Global Clinical Trials announces the acquisition of a long-time collaborator Larrey Ltd. GCT will now offer in-house regulatory affairs, clinical monitoring, site and project management, IMP and clinical trial materials logistics and other support in Estonia, Latvia, and Lithuania.

Larrey CRO has been providing clinical research services in the Baltic States since 2011, accumulating excellent knowledge of both local market and international standards of the industry. Sergejus Krachmalis, the founder of Larrey Ltd., is appointed as the Head of GCT Baltic States and Global Clinical Lead.

Sergejus possesses rich experience in the field of clinical trials. Following his graduation from Kaunas Medical University in 2001, he worked as a lector in Vilnius Medical School. After entering clinical research, he got to be involved in all the essential parts of a drug development cycle. Sergejus will bring over 20 years of expertise as a CRA, Project Manager and Global Clinical Operations Lead. He worked with small and top 10 CROs and from the side of the sponsor companies, running regional and global studies, including those involving USA.

“It is a great honor for me to join Global Clinical Trials as Head of Baltic States. Both GCT and Larrey created long-term and fruitful relationships in the industry. I believe our mutual exchange of knowledge, global experience and regional focus will be beneficial for our Clients. It is my pleasure to be representing this region of EU and show opportunities it has to offer.”

Estonia, Latvia, and Lithuania can provide many valuable advantages to a global clinical trial. Quick clinical trial start-up is governed by the regulatory process similar to that in the EU and takes from 1 to 3 months on average. A significant incidence of oncological, cardiovascular, neurological, endocrinologic, psychiatric diseases ensures fast enrollment and patient retention. Experienced medical staff and good clinical practice (GCP) incorporated into national laws guarantee a standard of clinical research and data integrity. Import licenses are not required for IMP, laboratory kits, medical devices transport within the European Union, which makes logistics easy.

“It is a pleasure to have Sergejus and his company join us. Despite the global pandemic, we at GCT continue to put efforts in our further expansion to the most attractive countries for clinical trials. Sergejus expertise matches perfectly GCT priority therapeutic areas: oncology, genetic and rare disorders, ophthalmology, gastroenterology, reproductive health, and CNS disorders. We are thrilled with Larrey brining three new countries to GCT’s global end-to-end CRO service offerings.” said Dr. Jeffrey Apter, GCT President.

GCT Announces Expansion to the Country of Georgia

Princeton, NJ, USA, Nov 2, 2020

Yesterday Global Clinical Trials, LLC announced the launch of full-service clinical operations in Georgia by opening a new office in Tbilisi. Having successfully conducted clinical trials there, we are now pleased to announce this new corporate milestone: 

“Speaking from our team’s hands-on experience, this country has the potential to offer high-quality resources and competitive enrollment rates in many indications. We are excited to broaden our geographic coverage by adding Georgia to our map of operations, and to start offering it to our clients” – GCT CEO, Dr. Eugene Selivra.

Shota Jibuti, MD is appointed the Managing Director at GCT Georgia. Before entering clinical research, he worked in the Pharmaceutical Activity department of the Ministry of Health of Georgia for over 6 years. He served as an expert, accountable for scientific-technical (pharmacological) and administrative expertise of pharmaceutical products, intended for national registration procedure in Georgia. In addition, he is the author of numerous scientific articles. Later, working at several global CROs, he gained experience in ophthalmology, cardiology, oncology, urology, CNS and gastro-intestinal diseases.

“I am incredibly excited and honored to lead GCT team in Georgia. I am extremely grateful for the opportunity to become a member of the hard-working GCT team driven to deliver an outstanding service and exceeding expectations of our clients within the clinical trials in Georgia, as well as globally.”

Georgia has a population of 3.75 million people and is located at the crossroads of Western Asia and Eastern Europe on the coast of the Black Sea. Georgia has become an attractive region for clinical trials due to the recent development of the country’s Healthcare System, as well as one of the shortest CTA review timelines within Europe.

In the last 5 years, Georgia has focused on reduction of disease burden and mortality. Currently, there are around 300 clinical centers and hospitals, most of which are located in Tbilisi. In total, Georgia has more than 16 000 hospital beds.

Many local and global companies conduct clinical research in Georgia due to numerous advantages the country has to offer:

  • Full compliance with the ICH – GCP
  • Clear regulatory requirements and a simplified process of documents submission
  • Single license for import and export of the study drug
  • Highest quality of data inspected and accepted by EMA and FDA
  • Quick Start-up. It takes only 2 months to initiate a study
  • Qualified Medical and clinical centers with experience in clinical studies
  • Highly motivated investigators, site teams and patients
  • Recognized International standards for disease treatment and prevention

First Patient In Acute Infection Clinical Trial In Russia

Despite of COVID-19 challenging the routine of clinical trials worldwide, Global Clinical Trials has successfully randomized the first patient into a clinical trial evaluating the efficacy of IP in the sore throat pain relief.

This is a phase IV, multicenter, randomized, non-inferiority trial aiming to enroll over 300 patients globally.

The first patient was enrolled only 4 days after the site activation.

“We are honored to manage this clinical program in Russia and to be able to deliver FPI shortly after site initiation. At the same time, keeping patients, site and GCT staff safe is our ultimate focus. We are hoping the trial will be a success and will improve treatment options for patients in Eastern Europe,” said Eugene Selivra, MD, CEO of Global Clinical Trials.

Database Locked for the Rare Disease Pediatric Study

GCT team is proud of taking part in the achievement of the major milestone for the Phase III clinical trial. The study is being successfully conducted, amidst the present difficult global environment, in pediatric patients suffering from a rare neurological disease. It is a randomized, double-blind, placebo-controlled trial followed by a long-term open label treatment. In January 2020, GCT successfully completed the enrollment of patients in Russia. We have now reached the next milestone – the Database Lock.

Despite all the challenges caused by the pandemic, the GCT team was able to follow each patient closely and ensure they complete all the required assessments, keeping trial participants safe during the treatment stage. This trial required a high level of GCT expertise and involvement, which the team successfully delivered.

“The sponsor of this trial, a US Pharmaceutical company, demonstrated an incredible level of trust in GCT, for which we are extremely grateful. We hope that our professional relationship will continue to grow and develop in the future,” – Dr. Eugene Selivra, GCT CEO.

Multiple Sclerosis Observational Study in Georgia

Global Clinical Trials is managing its first local project in the country of Georgia. It is a recently awarded observational Phase IV clinical trial in Multiple Sclerosis.

GCT team is performing local management of the multinational study sponsored by an international Big Pharma. It includes trainings, regulatory documentation handling, adjustment and submission of amendments, site monitoring and close-out, and the eTMF maintenance.

Georgia is known for the fast regulatory approval of clinical trials, which only takes 30 working days. The submission package is similar to that in the EU countries.

While the clinical trials market in Georgia is still emerging, the key aspect is to find the CRO with local expertise. As a boutique CRO with the focus on CNS and Neurology clinical studies, we are proud to share our insight during this trial. The executive oversight is provided from both GCT President, Dr. Jeffrey Apter and CEO, Dr. Eugene Selivra who are trained psychiatrists with 50+ years of combined experience in clinical research.

For any inquiries about CNS and Neurology clinical trials, and clinical trials in Georgia, please get in touch with GCT BD team at bd@gctrials.com.

New Phase I Breast Cancer Study Awarded in Russia

GCT has been awarded a new Phase I clinical trial in patients with breast cancer. It aims to prove the safety, tolerance and pharmacokinetics of the Investigated Medical Product (IMP) using the dose escalation method. The study will be conducted in Russia with enrolling 60 patients who suffer from palindromic or refractory metastatic breast cancer. The project is sponsored by a Russian biotechnology start-up company specializing in oncology research.

The clinical trial is now in the active start-up process, and the regulatory submission is expected in early September. Global Clinical Trials is currently in the process of performing medical and regulatory review of documents prior to the RA submission. GCT monitors will soon be performing Pre-Study site visits (PSVs).

Chronic Pancreatitis Study: First Patient In (FPI)

GCT is proud to announce successful enrollment of the first patient in Russia in the Chronic Pancreatitis clinical trial. The multinational Phase II randomized double-blind Gastroenterology trial is aiming to enroll over 160 patients in total. GCT is managing the study in Russia and Ukraine and covering the full-service clinical support.

The 1st randomized patient was recently screened and approved for the study. In general, the sites in Russia have preliminarily shown a higher enrollment potential in comparison to sites in other countries. There are several dozen potential subjects who currently are in the pre-screening stage. These patients will be randomized for the study in the upcoming few weeks.

The pre-study and start-up activities for this study have been accomplished on time despite the restrictions and obstacles due to the COVID-19 pandemic. GCT team is looking forward to reaching the further milestones.

GCT to Conduct a Rare Pulmonary Disease Study

GCT has been awarded a new clinical trial in Ukraine and Russia. A Phase II multinational study in subjects with Idiopathic Pulmonary Fibrosis (IPF) is designed to investigate the safety, efficacy, and pharmacokinetics of the investigational product. IPF is a disease that is characterized by scarring of the lungs. As condition develops, it becomes harder and harder to breathe. There’s no cure for this disease, however medications can help manage the symptoms.

We are providing full-service clinical support in both countries, including feasibility analysis and site identification, regulatory support, monitoring, site management and financial management. The trial is currently in the start-up stage in Ukraine and Russia. Regulatory submission preparations and pre-study visits to the selected sites are in progress.

“Idiopathic Pulmonary Fibrosis is a serious and devastating disease, often with poor prognosis. We look forward to conducting this important trial aimed at improvement of patients’ quality of life. It enhances our extensive experience in rare diseases and, ultimately, will provide patients with more treatment options,” – Dr. Jeffrey Apter, GCT President.

Multinational Natural History Rare Disease Study Extension

Global Clinical Trials, LLC is awarded to run the rare disease project globally. The trial is already ongoing and managed by GCT in India. In addition to that, the sites will now open in Western and Mediterranean Europe, Western Asia, and Great Britain. GCT is providing regulatory, clinical trial management, EU Legal representation and GDPR support for this study.

The indication under research is an extremely rare genetic disease inherited as an autosomal recessive trait. It is characterized by variety of gastrointestinal and neurological symptoms that will result in complications, which heavily affect the lives of patients and their families.

“To manage such an important and geographically diverse project is a significant milestone for GCT. We are thrilled to be supporting the Sponsor across the globe using our on-the ground personnel,” – Dr. Eugene Selivra, GCT CEO.

COVID-19 study to be conducted in Russia and Ukraine

Global Clinical Trials has been awarded a randomized, double-blind, placebo-controlled phase II clinical study in patients with COVID-19, SARS CoV-2 infection. GCT will manage project in Ukraine and Russia targeting to enroll about 50 hospitalized subjects in 1,5 months. The objective of the trial it to evaluate the drug safety and its effect on inflammation.

“On behalf of the Global Clinical Trials team, we are grateful and enthusiastic to contribute to the development of treatments against the Coronavirus Disease. I look forward to seeing what this project can bring to the global blueprint for patients affected by the virus,” – Dr. Eugene Selivra, GCT CEO.

The study has been contracted out to GCT this month, and our team is progressing quickly with start-up activities to ensure accelerated submission for this highly prioritized trial.

GCT supports the White Nights Ophthalmology Congress going virtual

The “White Nights” International Ophthalmology Congress, taking place annually in St. Petersburg, Russia in late May, is one of the leading Ophthalmology events in the region. Every year the Congress attracts over 2 000 participants from all over Russia, Europe, the Middle East, and the Americas. For over a decade GCT has been the Exclusive Information Partner of the Congress, running the Congress website, providing organization and participant registration services.

This year, due to the global pandemic, the congress has been held as a hybrid event, with the speakers joining from the traditional congress venue rooms or remotely, and the registered participants accessing the video streams being broadcasted from the venue. Communication with the speakers was facilitated through an interactive chat in the member’s area on the congress website.

The virtual Congress has seen substantial growth in the participant numbers reaching over 5,400. GCT is proud to support the Congress in these challenging circumstances. We share our organizational expertise and technical capabilities to aid the delivery of the most recent and promising developments and updates in treatment to the medical professionals and the ophthalmic community.

Pictured: Plenary session of the Congress, 2019

Multisystem Rare Disease Study in India

Global Clinical Trials, LLC is initiating a new project in India. It is a Natural History Study of a rare congenital disease to be conducted at several clinical sites across the country.

GCT will provide clinical trial solutions for the study including the project management activities, site management activities, full regulatory support and clinical monitoring. The study is expected to initially last over 2 years. The project will be managed by Umakanta Sahoo, PhD, MBA who has an extensive background and over 20 years of experience in clinical research.

GCT has conducted numerous clinical studies in Rare Diseases and is familiar with Key Opinion Leaders (KOLs) in many regions, including India, Eastern and Central Europe and the USA. The company’s expertise is reaffirmed by an extremely high percentage of repeat business due to successful and timely completion of our projects.


Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2021 Global Clinical Trials, LLC

All rights reserved.